无标签糖基化重组人MFG-E8治疗急性肾损伤
本研究在大鼠中评估无标签糖基化重组人MFG-E8的药代动力学,并在成年雄性C57BL6小鼠双侧肾缺血30分钟后,于再灌注时腹腔注射生理盐水(溶媒)或20 μg/kg该药物治疗。结果:治疗组48小时血尿素氮和肌酐显著降低,24小时和48小时TNF-α、IL-6、IL-1β水平及24小时肾脏mRNA表达显著降低,48小时肾小管损伤和TUNEL阳性细胞数明显减少;10天生存研究显示治疗改善生存。作者结论认为该药物对缺血再灌注诱导的AKI具有保护作用,可能具有进一步开发为安全有效AKI治疗的潜力。
要点
- 成年雄性C57BL6小鼠双侧肾缺血30分钟,再灌注即刻腹腔注射无标签糖基化重组人MFG-E8 20 μg/kg。
- 治疗组48小时血尿素氮和肌酐较溶媒组显著降低。
- 治疗组24小时和48小时TNF-α、IL-6、IL-1β水平降低,24小时肾脏mRNA表达亦显著降低。
- 治疗组48小时肾小管损伤和TUNEL阳性细胞数明显减少。
- 10天生存研究中,再灌注时给药改善生存。
适用人群与场景
- 成年雄性C57BL6小鼠,双侧肾缺血30分钟后再灌注模型。
- Sprague-Dawley大鼠用于药代动力学评估。
处置流程与药物剂量
- 再灌注即刻腹腔注射无标签糖基化重组人MFG-E8 20 μg/kg(小鼠)。
- 对照为腹腔注射生理盐水(溶媒)。
研究设计与关键结果
- 药代动力学:AKI大鼠接受无标签rhMFG-E8后的半衰期与治疗对照大鼠相似。
- 48小时肾功能:血尿素氮和肌酐升高,治疗显著降低这些指标。
- 炎症因子:24小时和48小时TNF-α、IL-6、IL-1β升高,治疗降低这些水平;24小时肾脏mRNA表达升高,治疗显著降低。
- 组织学:48小时肾小管损伤和TUNEL染色细胞数增加,治疗明显减少。
- 生存:10天生存研究中,再灌注时给药改善生存。
证据类型、等级与局限
- 证据类型:动物实验(大鼠药代动力学、小鼠缺血再灌注AKI模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这种新的人细胞表达无标签rhMFG-E8对缺血再灌注诱导的AKI具有保护作用,可能有潜力进一步开发为安全有效的AKI治疗。
- 原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Acute kidney injury (AKI) can result from renal ischemia and reperfusion (I/R) and often occurs during surgical procedures in cardiac, liver, kidney transplantation, and trauma-hemorrhage. Milk fat globule epidermal growth factor-factor VIII (MFG-E8) functions as a bridging molecule to promote the removal of dying cells by professional phagocytes. Because MFG-E8 promotes clearance of apoptotic cells, we have explored its therapeutic potential in various organ injury conditions. To develop human MFG-E8 as a potential therapy, we have generated a human cell-expressed, and thus glycosylated, tag-free recombinant human (rh) MFG-E8 and tested its safety and biological activity in vitro . We hypothesize that the tag-free glycosylated rhMFG-E8 is protective in I/R-induced AKI and it can be developed as an effective therapy for AKI. Methods: To assess the pharmacokinetic properties of the tag-free rhMFG-E8, Sprague-Dawley rats were either untreated or treated with a bolus dose of the tag-free rhMFG-E8, blood collected at various time points and the recovery of human MFG-E8 in the blood were measured by ELISA. Adult male C57BL6 mice underwent bilateral renal ischemia for 30 min, and immediately upon reperfusion, mice were treated intraperitoneally with either normal saline (vehicle) or 20 μg/kg human cell expressed, glycosylated tag-free rhMFG-E8. At either 24 h or 48 h after I/R, blood and kidneys were harvested for further analysis. In separate cohorts of mice after I/R and treatment, mice were observed for 10 days, and survival recorded. Results: AKI rats treated with the tag-free rhMFG-E8 had similar half-life as those in the treated control rats. At 48 h after I/R-induced AKI, renal function markers, blood urea nitrogen, and creatinine were increased and treatment with the tag-free rhMFG-E8 significantly decreased these markers. At both 24 h and 48 h after AKI, inflammatory cytokines, TNF-α, IL-6, and IL-1β were increased and treatment decreased these levels. The kidney mRNA expressions of these cytokines were also increased at 24 h after AKI and treatment significantly decreased those mRNA expressions. Histologically, at 48 h after AKI, tubular damage, and the number of TUNEL staining cells were increased and treatment markedly decreased these measurements. Administration of tag-free rhMFG-E8 at the time of reperfusion improved survival in a 10-day survival study. Conclusion: Our new human cell-expressed tag-free rhMFG-E8 is protective in I/R-induced AKI and it may have the potential to be further developed as a safe and effective therapy for AKI.
参考来源
- Zhang F, Ma G, Chaung W, et al. TAG-FREE GLYCOSYLATED RHMFG-E8 AS A THERAPY FOR ACUTE KIDNEY INJURY. Shock. 2024. PMID: 38691106. doi:10.1097/SHK.0000000000002382
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。